For
immediate release
|
8 May 2024
|
ALLIANCE
PHARMA
("Alliance", "Company" or the
"Group")
Management update
Alliance Pharma plc (AIM: APH), the
international healthcare group, announces that Peter Butterfield,
Chief Executive Officer ("CEO"), has decided to leave the business
in order to pursue other business interests. Following a
comprehensive search process, Nick Sedgwick has been appointed as
the new CEO, starting 13 May 2024. Peter will remain at Alliance
until 30 June 2024 to facilitate a thorough handover.
Peter joined the Board of Alliance in 2010 and became CEO in 2018, driving
a strategy to increase the focus on consumer healthcare and
extending the Company's global reach into APAC and the
US.
Nick Sedgwick brings thirty years of
consumer health experience across European, US and global roles at
major multinational companies such as Reckitt, Coty and Nestlé.
Most recently Nick was Regional Director for UK and Ireland
Consumer Health at Reckitt during which time he increased revenue
and improved profitability in the second largest market for the
company. Prior to this, Nick worked at Coty holding a number of
senior roles including Senior Vice President for Global Sales and
Commercial Capabilities, Senior Vice President Sales for the US
business and General Manager Consumer Beauty for UK and Ireland.
Throughout his career, Nick has worked in multiple countries,
always delivering high revenue growth through consumer-centric
strategies, high performance teams and excellence in
execution.
Camillo Pane, Chair of Alliance, said:
"The Board and I would like to thank
Peter for everything that he has done for Alliance. He led
Alliance's transition towards Consumer Healthcare and Group
revenues have almost doubled since he became CEO. We wish Peter
well in his future endeavours.
"We welcome Nick to Alliance and
look forward to working with him as he leads the Company through
the next phase of its growth and development."
Peter Butterfield, Chief Executive Officer of Alliance,
said:
"It has been a genuine privilege to
lead Alliance over the last six years through a period of growth
and transformation. I am very confident that the Company is in good
hands and look forward to seeing it go from strength to
strength."
Nick Sedgwick, Chief Executive Officer designate of Alliance,
said:
"I am really excited to be joining
Alliance at such an important time for the business. I look forward
to getting to know the Company in depth over the next few months
and working with the management team to deliver the next phase of
growth."
In
accordance with Schedule 2 (g) of the AIM Rules for Companies,
Nicholas John Sedgwick (aged 51 years) holds/has held the following
directorships/partnerships in the last five
years:
Current
directorships/partnerships
|
Previous directorships/partnerships
(last five years)
|
None
|
RB UK Commercial Limited
Proprietary Association of Great
Britain
Cosmetic, Toiletry and Perfumery
Association Limited
|
Mr
Sedgwick currently holds no ordinary shares in the
Company.
There are no further disclosures to made be under Schedule
2(g) of the AIM Rules for Companies.
For
further information:
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
Cora McCallum, Head of Investor
Relations & Corporate Communications
|
+ 44
(0)1249 705168
|
ir@allianceph.com
|
|
|
|
Buchanan
|
+ 44 (0)20 7466
5000
|
Mark Court / Sophie Wills
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
Freddie Barnfield / Duncan Monteith
/ Sher Shah
|
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0)20 7597
5970
|
Patrick Robb / Lydia
Zychowska
|
|
About Alliance
Alliance Pharma plc (AIM: APH) is a
growing consumer healthcare company. Our purpose is to empower
people to make a positive difference to their health and wellbeing
by making our trusted and proven brands available around the
world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 285 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands.
For more information on Alliance,
please visit our website: www.alliancepharmaceuticals.com